This approach enables the detection of immuno-captured bladder cancer cells by targeting their Epithelial Cell Adhesion Molecule (EpCAM) through the use of specific anti-EpCAM antibodies [47,48]. The gene discussed is EPCAM; the disease is urinary bladder carcinoma.